Cargando…

Controlling Cytokine Release Syndrome to Harness the Full Potential of CAR-Based Cellular Therapy

Chimeric Antigen Receptor (CAR)-based therapies offer a promising, targeted approach to effectively treat relapsed or refractory B cell malignancies. However, the treatment-related toxicity defined as cytokine-release syndrome (CRS) often develops in patients, and if uncontrolled, can be fatal. Grad...

Descripción completa

Detalles Bibliográficos
Autores principales:	Thakar, Monica S., Kearl, Tyce J., Malarkannan, Subramaniam
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2020
Materias:	Oncology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7006459/ https://www.ncbi.nlm.nih.gov/pubmed/32076597 http://dx.doi.org/10.3389/fonc.2019.01529

Ejemplares similares

The Fyn–ADAP Axis: Cytotoxicity Versus Cytokine Production in Killer Cells
por: Gerbec, Zachary J., et al.
Publicado: (2015)

Grading of cytokine release syndrome associated with the CAR T cell therapy tisagenlecleucel
por: Porter, David, et al.
Publicado: (2018)

Biomarkers of cytokine release syndrome and neurotoxicity related to CAR-T cell therapy
por: Wang, Zhenguang, et al.
Publicado: (2018)

Interleukin Inhibitors in Cytokine Release Syndrome and Neurotoxicity Secondary to CAR-T Therapy
por: Ferreros, Puri, et al.
Publicado: (2022)

Emerging approaches for preventing cytokine release syndrome in CAR-T cell therapy
por: Balagopal, Srinivas, et al.
Publicado: (2022)

Harnessing the Gut Microbiota to Potentiate the Efficacy of CAR T Cell Therapy
por: Gabrielli, Giulia, et al.
Publicado: (2023)

IL-22 from conventional NK cells is epithelial regenerative and inflammation protective during influenza infection
por: Kumar, Pawan, et al.
Publicado: (2012)

Correction to: Grading of cytokine release syndrome associated with the CAR T cell therapy tisagenlecleucel
por: Porter, D., et al.
Publicado: (2018)

In-Vivo Induced CAR-T Cell for the Potential Breakthrough to Overcome the Barriers of Current CAR-T Cell Therapy
por: Xin, Tianqing, et al.
Publicado: (2022)

Clinical Relevance of Natural Killer Cells Following Hematopoietic Stem Cell Transplantation
por: Palmer, Jeanne M, et al.
Publicado: (2012)

Natural Killer Cells: Development, Maturation, and Clinical Utilization
por: Abel, Alex M., et al.
Publicado: (2018)

Cytokines Are at the Heart of It: Cytokine Release Syndrome Underlies Cardiovascular Effects of CAR T Cell
por: Catino, Anna B.
Publicado: (2020)

P1082: RESULTS FROM A PHASE 1/2 STUDY OF TANDEM, BISPECIFIC ANTI-CD20/ANTI-CD19 (LV20.19) CAR T-CELLS FOR MANTLE CELL LYMPHOMA
por: Shah, Nirav N, et al.
Publicado: (2023)

Fyn-ADAP signaling via Carma1-Bcl10-MAP3K7 signalosome exclusively regulates inflammatory cytokine production in NK cells
por: Rajasekaran, Kamalakannan, et al.
Publicado: (2013)

IL-22: An Evolutionary Missing-Link Authenticating the Role of the Immune System in Tissue Regeneration
por: Kumar, Pawan, et al.
Publicado: (2012)

Case Report: Cardiac Tamponade in Association With Cytokine Release Syndrome Following CAR-T Cell Therapy
por: Moriyama, Shohei, et al.
Publicado: (2022)

Mechanisms of cytokine release syndrome and neurotoxicity of CAR T-cell therapy and associated prevention and management strategies
por: Xiao, Xinyi, et al.
Publicado: (2021)

Cellular Immunotherapy and Locoregional Administration of CAR T-Cells in Malignant Pleural Mesothelioma
por: Belderbos, Robert A., et al.
Publicado: (2020)

Radiation and CAR T-cell Therapy in Lymphoma: Future Frontiers and Potential Opportunities for Synergy
por: Fang, Penny Q., et al.
Publicado: (2021)

IL-27 promotes NK cell effector functions via Maf-Nrf2 pathway during influenza infection
por: Kumar, Pawan, et al.
Publicado: (2019)

Hemofiltration Successfully Eliminates Severe Cytokine Release Syndrome Following CD19 CAR-T-Cell Therapy
por: Liu, Yanfen, et al.
Publicado: (2018)

Coexistence Of A Huge Venous Thromboembolism And Bleeding Tendency In Cytokine Release Syndrome During CAR-T Therapy
por: Liu, Haiyan, et al.
Publicado: (2019)

Severe cytokine release syndrome is associated with hematologic toxicity following CD19 CAR T-cell therapy
por: Juluri, Krishna R., et al.
Publicado: (2022)

Severe acute heart failure during or following cytokine release syndrome after CAR T-cell therapy
por: Yoshihara, Kyoko, et al.
Publicado: (2022)

Cytokine Release Syndrome and Associated Acute Toxicities in Pediatric Patients Undergoing Immune Effector Cell Therapy or Hematopoietic Cell Transplantation
por: Baumeister, Susanne H. C., et al.
Publicado: (2022)

A Metabolism Toolbox for CAR T Therapy
por: Xu, Xuequn, et al.
Publicado: (2019)

Potential Application of Chimeric Antigen Receptor (CAR)-T Cell Therapy in Renal Cell Tumors
por: Schepisi, Giuseppe, et al.
Publicado: (2020)

Continuous renal replacement therapy in cytokine release syndrome following immunotherapy or cellular therapies?
por: Constantinescu, Catalin, et al.
Publicado: (2020)

Case Report: Chimeric Antigen Receptor T Cells Induced Late Severe Cytokine Release Syndrome
por: He, Jinping, et al.
Publicado: (2022)

Harnessing Lactate Metabolism for Radiosensitization
por: Liu, Kevin X., et al.
Publicado: (2021)

Editorial: CAR T-Cell Therapies in Hematologic Tumors
por: Coscia, Marta, et al.
Publicado: (2020)

CAR T Cell Therapy for Pediatric Brain Tumors
por: Patterson, John D., et al.
Publicado: (2020)

Strategies for Dodging the Obstacles in CAR T Cell Therapy
por: Safarzadeh Kozani, Pooria, et al.
Publicado: (2021)

Focused evaluation of the roles of macrophages in chimeric antigen receptor (CAR) T cell therapy associated cytokine release syndrome
por: Guo, Hanfei, et al.
Publicado: (2022)

CAR-T cell therapy-related cytokine release syndrome and therapeutic response is modulated by the gut microbiome in hematologic malignancies
por: Hu, Yongxian, et al.
Publicado: (2022)

A major role for CD4(+) T cells in driving cytokine release syndrome during CAR T cell therapy
por: Boulch, Morgane, et al.
Publicado: (2023)

Editorial: Current Perspectives, Challenges and Advances in Cell Based Therapies
por: Thakar, Monica S., et al.
Publicado: (2020)

Harnessing the potential of CAR-T cell therapy: progress, challenges, and future directions in hematological and solid tumor treatments
por: Dagar, Gunjan, et al.
Publicado: (2023)

mTORC1 and mTORC2 differentially promote natural killer cell development
por: Yang, Chao, et al.
Publicado: (2018)

Understanding the Mechanisms of Resistance to CAR T-Cell Therapy in Malignancies
por: Cheng, Jiali, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_dooc0gnv11nq47mfl3q384ipf8